Retatrutide, a novel dual agonist of the GLP-1 target and glucose-dependent secreted polypeptide (GIP) target, is showing promising data in preliminary clinical trials . Ongoing inquiry indicates that https://bookmarkedblog.com/story268391/retatrutide-emerging-research-and-projected-medical-roles